Evidence map›Paper›PMID 40132061›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025

Machine Learning-based Prediction of Active Tuberculosis in People With HIV Using Clinical Data.

Lena Bartl, Marius Zeeb, Marisa Kälin, Tom Loosli, Julia Notter, Hansjakob Furrer, Matthias Hoffmann, Hans H Hirsch, Robert Zangerle, Katharina Grabmeier-Pfistershammer and 9 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Lena BartlDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
Marius ZeebDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0001-6822-1473
Marisa KälinDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0002-4924-9099
Tom LoosliDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
Julia NotterDivision of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.ORCID 0000-0003-4821-9995
Hansjakob FurrerDepartment of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID 0000-0002-1375-3146
Matthias HoffmannDivision of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital Olten, Olten, Switzerland.
Hans H HirschTransplantation & Clinical Virology, University of Basel, Basel, Switzerland.ORCID 0000-0003-0883-0423
Robert ZangerleDepartment of Dermatology, Venereology and Allergy, Medical University Innsbruck, Innsbruck, Austria.ORCID 0000-0002-5375-7299
Katharina Grabmeier-PfistershammerDepartment of Dermatology, Medical University Vienna, Vienna, Austria.
Michael KnappikDepartment of Respiratory Medicine, Klinik Penzing, Vienna, Austria.
Alexandra CalmyHIV Unit, Division of Infectious Diseases, University Hospital Geneva, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-1137-6826
Jose Damas FernandezDivision of Infectious Diseases, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-7724-6226
Niklaus D LabhardtDivision Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, Basel, Switzerland.
Enos BernasconiDivision of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano, Switzerland.ORCID 0000-0002-9724-8373
Huldrych F GünthardDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0002-1142-6723
Roger D KouyosDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
Katharina KusejkoDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0002-4638-1940
Johannes NemethDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.

Funding

Swiss National Science Foundation 201369Swiss National Science Foundation P 881
6 · The paper itself

Abstract

backgroundCoinfections of Mycobacterium tuberculosis (MTB) and human immunodeficiency virus (HIV) impose a substantial global health burden. Patients with MTB infection face a heightened risk of progression to incident active TB, which preventive therapy can mitigate. Current testing methods often fail to identify individuals who subsequently develop incident active TB.

methodsWe developed random forest models to predict incident active TB using patients' medical data at HIV-1 diagnosis. Training our model involved using clinical data routinely collected at enrollment from the Swiss HIV Cohort Study (SHCS). This dataset encompassed 55 people with HIV (PWH) who developed incident active TB 6 months after enrollment and 1432 matched PWH without TB enrolled between 2000 and 2023. External validation used data from the Austrian HIV Cohort Study, comprising 43 people with incident active TB and 1005 people without TB.

resultsWe predicted incident active TB with an area under the receiver operating characteristic curve of 0.83 (95% CI: .8-.86) in the SHCS. After adjusting for ethnicity and the region of origin and refitting the model with fewer parameters, we obtained comparable receiver operating characteristic curve values of 0.72 (SHCS) and 0.67 (Austrian HIV Cohort Study). Our model outperformed the standard of care (tuberculin skin test and interferon-gamma release assay) in identifying high-risk patients, demonstrated by a lower number needed to diagnose (1.96 vs 4).

conclusionsModels based on machine learning offer considerable promise for improving care for PWH, requiring no additional data collection and incurring minimal additional costs while enhancing the identification of PWH that could benefit from preventive TB treatment.

Indexed as

CoinfectionHIV InfectionsMachine LearningTuberculosisAdultCohort StudiesFemaleHumansIncidenceMaleMiddle AgedMycobacterium tuberculosisROC CurveSwitzerlandclinical risk scoreHIVmachine learningpredictiontuberculosis

Identifiers

PMID40132061
PMCPMC12497954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.